At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

If a language can be used to build web scrapers, it definitely needs to provide a graceful data visualization library. --- by dongdong. In the Golang ecosystem, there are not many choices for data ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

The Cambridge drugmaker said the smaller research organization "will match the needs of a prioritized preclinical portfolio." Biogen Inc. is making cuts to its research organization as the ...

Jane Grogan, Ph.D., took over Biogen’s research department in the ... “The new footprint of the research organization will match the needs of a prioritized preclinical portfolio and a shift ...